Peddock Capital Advisors LLC Sells 491 Shares of Novo Nordisk A/S (NYSE:NVO)

Peddock Capital Advisors LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,970 shares of the company’s stock after selling 491 shares during the quarter. Peddock Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $686,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the 2nd quarter worth about $25,000. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $28,000. Abound Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the last quarter. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the third quarter valued at about $42,000. Finally, Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth about $48,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $1.83 during midday trading on Monday, reaching $84.43. The stock had a trading volume of 7,282,971 shares, compared to its average volume of 7,401,729. The company has a market capitalization of $378.88 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company’s 50-day moving average is $100.35 and its 200 day moving average is $119.04.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.